There is perhaps no aspect of gender-affirming care that garners more attention than the use of puberty blockers.
They are described as ‘experimental’ and ‘controversial’ by those opposed to their use.
They’ve been banned in several U.S. states, and their use limited to “exceptional cases” in Sweden. The U.K. is currently reviewing the use of puberty blockers in NHS gender clinics.
All of this is justified by the contention that the science on puberty blockers is uncertain, due to a lack of good evidence, or conversely because the evidence points to serious harms.